<DOC>
	<DOCNO>NCT01678664</DOCNO>
	<brief_summary>Determine wether 24 month treatment everolimus prolongs progression free survival rate ( base central assessment ) embolisation ou chemoembolisation liver metastasis . - H0 24 month progression free survival rate le 35 % unacceptable - H1 24 month progression free survival rate great 35 % would show everolimus treatment beneficial , expect 24 month progression free survival rate 50 %</brief_summary>
	<brief_title>Everolimus After ( Chemo ) Embolization Liver Metastases From Digestive Endocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Well differentiate ( grade 1 2 accord WHO classification 2010 appendix 2 ) , histologicallyproven endocrine tumor gastrointestinal tract ( TENpath review mandatory ) , Measurable liver metastasis ( metastasis ) define RECIST v1.1 unresectable inaccessible radiofrequency ablationtype local treatment Hepatic arterial embolization chemoembolization indicate tumor size reduction , confirm multidisciplinary team ( MDT ) meeting , due progressive nature liver metastasis ( morphological progression past 12 month define RECIST v1.1 ) Age ≥ 18 year WHO performance status ≤ 2 No contraindication embolization chemoembolization everolimus Satisfactory laboratory assessment : Neutrophil count ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , Hb &gt; 10 g/dL , serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) , INR &lt; 1.3 ( &lt; 3 patient anticoagulant therapy ) ALT AST ≤ 5 x ULN , creatinine ≤ 1.5 x ULN , fast serum cholesterol ≤ 300 mg/dL 7.75 mmol/L triglyceride ≤ 2.5 x ULN ( either limit exceed , patient may include study institution appropriate lipidlowering therapy ) Complete resolution toxic effect prior treatment , persistence grade 1 ( CTCAE version 4.0 ) Minimum time since previous treatment : 28 day Patient inform sign informed consent form , verification eligibility criteria Patient cover French national health insurance scheme Duodenopancreatic neuroendocrine tumor Poorly differentiate and/or grade 3 endocrine tumor , Embolization chemoembolization indicate symptomatic control Prior hepatic TACE embolization Prior treatment mTOR inhibitor ( somatostatin analog control secretion permit ) Symptomatic bone metastasis ( metastasis ) Any uncontrolled progressive disease : hepatic failure , renal failure , respiratory failure , NYHA class IIIIV congestive heart failure , unstable angina , myocardial infarction , significant arrhythmia Interstitial lung disease Uncontrolled diabetes , define HbA1c &gt; 8 % Chronic corticosteroid immunosuppressant therapy Hypersensitivity everolimus , rapamycin derivative , one excipients Major surgery , open biopsy , significant traumatic lesion 28 day prior start investigational treatment Incompletely heal wound foreseeable need major surgery study Contraindication vascular occlusion procedure : Portal thrombosis , biliodigestive anastomosis Malignancy past 5 year , exception curatively treat basal cell skin carcinoma situ cervical cancer Foreseeable noncompliance Medical , geographic , sociological , psychological , legal situation would preclude patient complete study signing inform consent form Pregnant breastfeed woman Men woman childbearing potential use effective contraception Concurrent participation another investigational study could affect primary endpoint study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>gastrointestinal tract</keyword>
	<keyword>metastasis</keyword>
	<keyword>liver</keyword>
	<keyword>hepatic</keyword>
</DOC>